MarketPulse

biopharma

5 articles
BenzingaBenzinga··Vandana Singh

Ligand Pharmaceuticals Acquires XOMA for $739M to Expand Royalty Portfolio

Ligand Pharmaceuticals acquires XOMA Royalty for $739M, immediately accretive to EPS with 2026 guidance raised to $8.50–$9.50 per share.
LGNDXOMAXOMAOXOMAPacquisitionM&A
The Motley FoolThe Motley Fool··James Brumley

Viking Therapeutics Stock Could Double as GLP-1 Rival Advances Toward FDA Approval

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.
LLYNVOVKTXFDA approvalPhase 3 trials
Investing.comInvesting.com··Thomas Hughes

Insider Selling as a Contrarian Signal: Why $WM and $IONS Merit Investor Attention

Insider selling at $WM and $IONS masks attractive opportunities as institutional accumulation and strong fundamentals validate contrarian bullish cases for both stocks.
WMIONSdividend growthprofit-taking
The Motley FoolThe Motley Fool··James Brumley

ImmunityBio Surges 11% on First Asian Approval for Bladder Cancer Drug

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.
IBRXAsia-Pacific expansionbladder cancer
Investing.comInvesting.com··Nathan Reiff

Three Cash Flow Powerhouses Offer Shelter Amid Market Uncertainty

Three firms—Gilead Sciences, AbbVie, and Visa—offer defensive portfolios substantial free cash flow yields and capital returns amid 2026 market uncertainty.
VABBVGILDdividendpayments